Life Science Leader - Home Page
WEBVolastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow. OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in ...
Life Science Connect Podcast
WEBJun 25, 2021 — On today’s episode of the Life Science Connect podcast, Clinical Leader Chief Editor Ed Miseta talks about a virtual conference on patient centricity called “Focus On Patients,” covering the successes and challenges of putting patients at the center of clinical trials. 001: The JPM Conference. In this episode, Life Science Leader magazine ...
Articles by Ben Comer - Life Science Leader
WEBJun 28, 2024 — Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics.
Ahead Of The Curve On Radiopharmaceuticals - Life Science Leader
WEBJan 1, 2024 — Despite the negatives – a complicated supply chain, short half-life, and the radioactive fear factor – analysts are forecasting continued growth in radiopharmaceuticals (from approximately $5-7 billion in 2022 to $9-$13 billion in 2032), amid a shift in focus from diagnostics to therapeutics. In late December, Bristol Myers Squibb announced ...
FSP Or Full-Service Outsourcing For Clinical Trials? - Life Science …
WEBDec 3, 2013 — Functional service provider (FSP) partnerships have been gaining traction in recent years because of their potential to increase efficiency and flexibility in outsourcing without compromising quality. Well-defined services within the scope of a clinical trial project or program (e.g. data management, biostatistics, or medical writing) are good ...
Pharmaceutical Scientists' Salaries in 2023
WEBJan 15, 2024 — In fact, salaries were up among industry scientists as well as academic scientists (AAPS members) – mean annual base salary from principle, full-time employment in the U.S. as of June 1 (the date of the survey cut off) was $190,100, a 6.7% increase from 2022 ($178,100). Pharmaceutical scientists outside of the U.S. had average base salaries ...
Life Sciences Industry On Uptick In Virginia
WEBMay 1, 2019 — The numbers of biopharmaceutical companies and medical device and equipment companies increased by 37 and 31 percent respectively during 2014 to 2016. “The life sciences industry is on the uptick in Virginia,” says Gallagher. Most Virginia bioscience companies are locally grown, created by the state’s entrepreneurs or …
The FDA's Final Guidance On Early-Phase Cell Gene Therapy Trials
WEBApr 3, 2023 — By Tim Sandle, Ph.D.. The cell and gene therapy development process involves carefully screening variants of a product type. To aid this initial process and to ensure that suitable evidence is gathered so that effective variants of the product are taken through to later-stage trials, the FDA has produced finalized guidance, Studying Multiple Versions of a Cellular or Gene Therapy Product in an ...
About Life Science Leader
WEBLife Science Leader is an essential business publication for life science executives who work at everything from emerging biotechs to large pharmaceutical companies. Our content is designed to inform readers of industry best practices and motivate them to implement those practices in their businesses. Life Science Leader features interviews ...
Life Science Leader's Blog - Biopharma Research, Development …
WEBBy Wayne Koberstein Executive Editor, Life Science Leader. Follow Me On Twitter @WayneKoberstein. Friday, January 20, 2017. At the JPM conference, I spend the bulk of my time meeting with a string of companies, but as various as they are, they all share the common challenge of risk and uncertainty in the development of human therapeutics. For ...